Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 7-11 years (both inclusive) at the time of signing informed consent~* Tanner stage 1 (including subjects with premature adrenarche) at the time of signing informed consent~* BMI (body mass index) corresponding to above or equal to 30 kg/m\^2 for adults by international cut-off points (Cole et al 2000)1 and BMI below or equal to 45 kg/m\^2 as well as BMI above or equal to 95th percentile for age and gender~Exclusion Criteria:~* Subjects with secondary causes of childhood obesity (i.e., hypothalamic, genetic or endocrine causes)~* Subjects with confirmed bulimia nervosa disorder~* Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus as defined by glycosylated haemoglobin (HbA1C) Above or equal to 6.5 %~* History of pancreatitis (acute or chronic)~* Presence of severe co-morbidities as judged by the investigator~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)~* History of major depressive disorder within 2 years before randomisation

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).